Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
Filippi M, Grimaldi L, Conte A, Totaro R, Valente MR, Malucchi S, Granella F, Cordioli C, Brescia Morra V, Zanetta C, Perini D, Santoni L; EASIER Study Working Group. Filippi M, et al. Among authors: grimaldi l. J Neurol. 2024 Jan;271(1):340-354. doi: 10.1007/s00415-023-11955-0. Epub 2023 Sep 16. J Neurol. 2024. PMID: 37715789 Free PMC article.
Natalizumab in the pediatric MS population: results of the Italian registry.
Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, Filippi M, G GC; MS Study Group-Italian Society of Neurology. Ghezzi A, et al. Among authors: grimaldi lm. BMC Neurol. 2015 Sep 25;15:174. doi: 10.1186/s12883-015-0433-y. BMC Neurol. 2015. PMID: 26407848 Free PMC article.
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group. Comi G, et al. J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23. J Neurol. 2017. PMID: 29063244 Free PMC article. Clinical Trial.
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis.
D'Amico E, Zanghì A, Sciandra M, Lanzillo R, Callari G, Cortese A, Lus G, Lucchini M, Buccafusca M, Bonavita S, Gallo A, Curti E, Gajofatto A, Signoriello E, Bisecco A, Gobbin F, Ferrò MT, Ferrazzano G, Sparaco M, Valentino P, Mirabella M, Granella F, Bresciamorra V, Grimaldi LME, Patti F; ITALIAN-DIME-TERI group. D'Amico E, et al. J Neurol. 2020 Oct;267(10):3008-3020. doi: 10.1007/s00415-020-09959-1. Epub 2020 Jun 6. J Neurol. 2020. PMID: 32506391
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, Di Filippo M, Dattola V, Fantozzi R, Ferraro E, Filippi MM, Gasperini C, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, Marfia GA, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L. Bucello S, et al. Among authors: grimaldi lme. J Neurol. 2021 Aug;268(8):2922-2932. doi: 10.1007/s00415-021-10455-3. Epub 2021 Feb 22. J Neurol. 2021. PMID: 33616742
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
Centonze D, Fantozzi R, Buttari F, Grimaldi LME, Totaro R, Corea F, Marrosu MG, Confalonieri P, Cottone S, Trojano M, Zipoli V. Centonze D, et al. Front Neurol. 2021 Apr 22;12:637615. doi: 10.3389/fneur.2021.637615. eCollection 2021. Front Neurol. 2021. PMID: 33967938 Free PMC article.
Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.
Lus G, Bassano MA, Brescia Morra V, Bonavita S, Gallo A, Maimone D, Malerba L, Maniscalco GT, Saccà F, Salemi G, Turrini R, Cottone S, Sessa E, Buccafusca M, Grimaldi LME. Lus G, et al. Among authors: grimaldi lme. Neurol Sci. 2023 Jan;44(1):45-58. doi: 10.1007/s10072-022-06402-3. Epub 2022 Sep 17. Neurol Sci. 2023. PMID: 36114980 Free PMC article. Review.
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferrò MT, Rilla MT, Gandoglia I, Gazzola P, Brichetto G, Pasquali L, Grimaldi L, Ulivelli M, Marinelli F, Cordera S, Clerico M, Conte A, Salvetti M, Battaglia MA, Franciotta D, Uccelli A, Sormani MP; CovaXiMS Study Group. Schiavetti I, et al. Among authors: grimaldi l. Eur J Neurol. 2023 Aug;30(8):2357-2364. doi: 10.1111/ene.15830. Epub 2023 May 28. Eur J Neurol. 2023. PMID: 37154406 Free article.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP; CladStop study group. Schiavetti I, et al. Eur J Neurol. 2024 Jun;31(6):e16250. doi: 10.1111/ene.16250. Epub 2024 Mar 28. Eur J Neurol. 2024. PMID: 38549186 Free PMC article.
432 results